mynth
10/2026MajorityLBO

Archimed takes majority stake in 3verest

UNITED KINGDOM IT Services / Infrastructure & Cloud / Hosting / Datacenter REV £5–25M

Context

ARCHIMED acquired a majority stake in 3verest, the British medical imaging hosting company, in October 2026, investing through its MED III fund. Founder and chief executive Scott Crawford, who had built the business since 2016 without outside capital, kept a significant shareholding and continued to lead it. Founded in 2016 and headquartered in London, 3verest stores and manages the medical images hospitals and clinics produce. Scans, X-rays and pathology slides accumulate over decades, must remain retrievable for as long as the law requires, and cannot be held just anywhere: health data is subject to rules that tie its storage to a given jurisdiction. The company owns and operates its own data centres rather than reselling capacity from the large cloud providers, which allows it to guarantee where each archive physically sits and under which law it falls. It works alongside the vendors of the picture archiving systems that radiology departments use day to day, holding the certifications each market demands, including a SOC 2 attestation. Its customers are healthcare providers across the European Union, the United Kingdom, the United States, Canada and Asia-Pacific, served from offices in London, Sydney, Chicago and Munich. ARCHIMED invested to fund the company’s expansion into continental Europe, to widen the certifications it holds and to deepen its relationships with imaging vendors. It also intended to extend the service beyond radiology, which generates the largest archives, into cardiology, pathology and other specialties producing high volumes of images. ARCHIMED invests exclusively in healthcare companies, across medical technology, diagnostics, pharmaceutical services and healthcare software and infrastructure, a field it had identified as a priority before approaching 3verest.

3verest, which reported an EBITDA margin of [members only] in FY 2025, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the TMT (Tech, Media, Telecom) sector (14.6x in 2026).

-> Deep-dive in TMT (Tech, Media, Telecom) market trends

Ent. Value

[members only]

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (GBP)

FREE VIEW
Year
Rev
EBITDA
EBIT
FY 2025
11m
£5–25M
[members only]
2024
£5–25M
£5–25M
[members only]

Other operations with Archimed

Other operations with Archimed
DateAcquirerTargetCountrySector
11/2023ARCHIMEDINSTEMUNITED KINGDOMHealthcare
09/2016ARCHIMEDPOLYPLUSFRANCER&D Biotech

Similar deals in IT Services

Similar deals in IT Services
DateAcquirerTargetCountrySector
10/2026KESTERDATABALANCENETHERLANDSMSP (Managed Services)
10/2026VISTA EQUITY PARTNERSHID PKI BUSINESS UNITUNITED STATESCybersecurity Services
10/2026ICGTRUSTTEAMBELGIUMMSP (Managed Services)
10/2026THOMA BRAVOVARONIS SYSTEMSUNITED STATESCybersecurity Services
09/2026ITC FEDERALCAPGEMINI GOVERNMENT SOLUTIONSUNITED STATESConsulting & Integration
09/2026SAMSUNG ELECTRONICS / EQT PARTNERS / PSG EQUITYMISTRAL AIFRANCEData & AI Consulting
09/2026SOFTCATGDTUNITED STATESIT Services
09/2026MAIN CAPITAL PARTNERSQBEESGERMANYMSP (Managed Services)
09/2026ITC FEDERALAPRIVA ISSUNITED STATESCybersecurity Services
08/2026COLLANA GROUPNETWISEPOLANDConsulting & Integration

REFERENCES

Revenue range: REV £5–25M

EBITDA range: £5–25M

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of 3verest by Archimed are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: 3verest

Acquirer: archimed

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in 3verest, a British company specialised in Infrastructure & Cloud, by Archimed in 2026, structured as a leveraged buyout (LBO).

What were 3verest’s revenue and EBITDA at the time of the deal?

At the time of the transaction, 3verest reported annual revenue of £11m, with EBITDA estimated in the £5–25M bracket (FY 2025). Detailed financial figures are available to members.

How does the valuation of 3verest compare to benchmarks in the TMT (Tech, Media, Telecom) sector?

Transaction multiples for this specific deal are exclusively reserved for mynth members. Nevertheless, transactions tracked by mynth in this sector reveal an average benchmark multiple of 14.6x EBITDA during 2026.

What sources support the information on this transaction?

Data on this transaction was compiled from the official corporate announcement published by the parties, combined with independent reporting from specialized financial and M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.